Rhumbline Advisers Raises Position in UroGen Pharma Ltd. (NASDAQ:URGN)

Rhumbline Advisers boosted its stake in UroGen Pharma Ltd. (NASDAQ:URGN) by 37.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 50,477 shares of the company’s stock after buying an additional 13,681 shares during the quarter. Rhumbline Advisers owned approximately 0.22% of UroGen Pharma worth $847,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. BNP Paribas Financial Markets raised its holdings in UroGen Pharma by 40.4% in the 4th quarter. BNP Paribas Financial Markets now owns 22,996 shares of the company’s stock valued at $345,000 after acquiring an additional 6,617 shares during the last quarter. RTW Investments LP raised its holdings in UroGen Pharma by 101.4% in the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock valued at $25,902,000 after acquiring an additional 869,344 shares during the last quarter. Superstring Capital Management LP acquired a new stake in UroGen Pharma in the 4th quarter valued at about $3,831,000. Parkman Healthcare Partners LLC raised its holdings in UroGen Pharma by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 175,500 shares of the company’s stock valued at $2,632,000 after acquiring an additional 30,189 shares during the last quarter. Finally, Sierra Summit Advisors LLC acquired a new stake in UroGen Pharma in the 4th quarter valued at about $218,000. 91.29% of the stock is owned by hedge funds and other institutional investors.

UroGen Pharma Stock Down 4.2 %

UroGen Pharma stock opened at $12.97 on Tuesday. UroGen Pharma Ltd. has a fifty-two week low of $10.60 and a fifty-two week high of $20.70. The company has a debt-to-equity ratio of 3.23, a quick ratio of 7.93 and a current ratio of 8.15. The firm has a 50 day moving average price of $14.72 and a 200 day moving average price of $14.73. The company has a market capitalization of $304.20 million, a PE ratio of -3.81 and a beta of 1.11.

UroGen Pharma (NASDAQ:URGN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The company had revenue of $21.85 million for the quarter, compared to analysts’ expectations of $23.69 million. Research analysts expect that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

URGN has been the subject of a number of recent research reports. Guggenheim initiated coverage on shares of UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price objective for the company. Oppenheimer raised their price target on shares of UroGen Pharma from $32.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, June 14th. LADENBURG THALM/SH SH raised their price target on shares of UroGen Pharma from $48.00 to $53.50 and gave the stock a “buy” rating in a report on Friday, June 14th. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a report on Wednesday, August 14th.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.